Prothena Corporation plc

PRTA Healthcare Biotechnology

Prothena Corporation plc’s revenue for fiscal 2025 (year ended December 2025) was $9.7 million, down 92.8% from fiscal 2024. In the quarter to June 2026, revenue fell 77.2%, EPS grew 84.6% and free cash flow grew 44.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

8.42 0.01 −0.12%
Market cap
$432.8M
P/E
0.0×
Fwd P/E
188×
Dividend yield
—
F-score
2/9
Altman Z
−0.24
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

2 2 3 5
ROE
(67.63%) (63.62%) (40.30%) (14.39%)
ROA
(59.18%) (55.86%) (35.77%) (12.54%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(96.38%) (88.28%) (48.98%) (15.55%)
Average Days of Receivables
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(3.50) (3.04) (1.51) (1.17)
Free Cash Flow
(188.22) (163.72) (81.34) (60.80)
Other line items

Show all line items

Columns are period end dates